Teyi Pharmaceutical GroupLtd Valuation

Q: What is the Fair Price of 002728 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

002728 (CN¥9.23) is trading above our estimate of [[fair value]] (CN¥0.1)

Is 002728 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002728 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002728 (CN¥9.23) is trading above our estimate of fair value (CN¥0.1)

Significantly Below Fair Value: 002728 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002728?

Key metric: As 002728 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 002728. This is calculated by dividing 002728's market cap by their current earnings.
What is 002728's PE Ratio?
PE Ratio	65x
Earnings	CN¥70.70m
Market Cap	CN¥4.60b

002728 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6x
Enterprise Value/EBITDA	31.7x
PEG Ratio	1.4x

Price to Earnings Ratio vs Peers

How does 002728's PE Ratio compare to its peers?

The above table shows the PE ratio for 002728 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	46.3x
603676 Tibet Weixinkang Medicine	18.2x	n/a	CN¥4.5b
603566 Pulike Biological Engineering	43.3x	33.1%	CN¥4.4b
002644 LanZhou Foci PharmaceuticalLtd	99.6x	n/a	CN¥4.6b
002393 Tianjin Lisheng PharmaceuticalLtd	24x	n/a	CN¥4.5b
002728 Teyi Pharmaceutical GroupLtd	65x	47.2%	CN¥4.6b

Price-To-Earnings vs Peers: 002728 is expensive based on its Price-To-Earnings Ratio (65x) compared to the peer average (46.3x).

Price to Earnings Ratio vs Industry

How does 002728's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 002728 is expensive based on its Price-To-Earnings Ratio (65x) compared to the CN Pharmaceuticals industry average (29.9x).

Price to Earnings Ratio vs Fair Ratio

What is 002728's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002728 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	65x
Fair PE Ratio	37.1x

Price-To-Earnings vs Fair Ratio: 002728 is expensive based on its Price-To-Earnings Ratio (65x) compared to the estimated Fair Price-To-Earnings Ratio (37.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Dong-E-E-JiaoLtd

CN¥36.7b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥57.18

-1.8%

13.3%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.20

-3.1%

-24.5%

Hunan Jiudian Pharmaceutical

CN¥11.8b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.80

-1.8%

12.8%